Automatic surgical phase recognition-based skill assessment in laparoscopic distal gastrectomy using multicenter videos
ConclusionThe developed model had high accuracy in phase-recognition tasks and has the potential for application in automatic surgical skill assessment systems. (Source: Gastric Cancer)
Source: Gastric Cancer - December 1, 2023 Category: Gastroenterology Source Type: research
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy
ConclusionsTADNI is a special morphological subtype with poorer prognoses and unique molecular characteristics, which might benefit from CXCR1/CXCR2 inhibitors.Graphical abstract (Source: Gastric Cancer)
Source: Gastric Cancer - November 29, 2023 Category: Gastroenterology Source Type: research
Clinical outcomes of Epstein –Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy
ConclusionsEBVaGC accounted for 5% of metastatic/unresectable GCs. While EBVaGC was not associated with better response to or PFS following first-line cytotoxic chemotherapy, it showed a trend toward better overall survival. (Source: Gastric Cancer)
Source: Gastric Cancer - November 25, 2023 Category: Gastroenterology Source Type: research
Randomized controlled trial comparing the costs of gastric cancer screening systems between serological risk-based upper gastrointestinal endoscopy and the existing barium photofluorography: gastric cancer screening labeled by serum examination in place of aged gastric cancer organized screening systems (GALAPAGOS study)
ConclusionsThe testing cost per participant turned out to be higher in the ABC-Endo group than in the Ba-Endo group. This superiority trial, based on the hypothesis that the cost of testing is lower for ABC-Endo than for Ba-Endo, was rejected. (Source: Gastric Cancer)
Source: Gastric Cancer - November 25, 2023 Category: Gastroenterology Source Type: research
5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer
ConclusionsThe survival of the four-course arm was slightly but consistently inferior to that of the eight-course arm. Eight-course S-1 should thus remain the standard adjuvant chemotherapy for pathological stage II gastric cancer. (Source: Gastric Cancer)
Source: Gastric Cancer - November 21, 2023 Category: Gastroenterology Source Type: research
Helicobacter pylori testing prior to or at gastric cancer diagnosis and survival in a diverse US patient population
ConclusionsThese findings supportHp testing and treatment for patients at risk of or diagnosed with GC, and suggestHp treatment may provide an opportunity to reduce GC mortality disparities in the US. (Source: Gastric Cancer)
Source: Gastric Cancer - November 20, 2023 Category: Gastroenterology Source Type: research
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
ConclusionsIn the AGAMENON-SEOM registry, younger patients with GCYA exhibited more aggressive clinicopathological features, and despite receiving more aggressive treatments, similar efficacy outcomes and toxicity profiles were achieved compared to their older counterparts.MiniabstractIn the AGAMENON-SEOM registry, GEAC in < 45 years showed more aggressive clinicopathological features and, although treated with more intense first-line CT regimens, similar efficacy outcomes and toxicity were achieved compared to older patients. (Source: Gastric Cancer)
Source: Gastric Cancer - November 15, 2023 Category: Gastroenterology Source Type: research
Effect of preoperative chemotherapy on the histopathological classification of gastric cancer
ConclusionOur results suggest that accurate determination of histological subtype on gastric cancer biopsies is suboptimal but that the impact of preoperative chemotherapy on histological subtype is negligible. (Source: Gastric Cancer)
Source: Gastric Cancer - November 10, 2023 Category: Gastroenterology Source Type: research
Acknowledgment to Reviewers
(Source: Gastric Cancer)
Source: Gastric Cancer - November 8, 2023 Category: Gastroenterology Source Type: research
Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations
ConclusionWhile MR analysis suggests a linear association between BMI and GC in those of European ancestry, nonlinear MR hints at a U-shaped association in Koreans. This suggests the association between BMI and GC risk may vary according to ethnic ancestry. (Source: Gastric Cancer)
Source: Gastric Cancer - November 2, 2023 Category: Gastroenterology Source Type: research
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
ConclusionsAlthough the study did not meet its primary end point, nivolumab and paclitaxel for AGC demonstrated a durable response with manageable toxicity profiles. Genomic analysis or plasma cytokine analysis may provide information for the selection of patients who would benefit more from immunotherapy combined with chemotherapy. (Source: Gastric Cancer)
Source: Gastric Cancer - October 31, 2023 Category: Gastroenterology Source Type: research
N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation
ConclusionsIn conclusion, this study highlighted that OIP5-AS1 is an oncogenic m6A-modified long non-coding RNA (lncRNA) in GC and that IGF2BP3/OIP5-AS1/hnRNPA1 axis may provide a potential diagnostic or prognostic target for GC. (Source: Gastric Cancer)
Source: Gastric Cancer - October 28, 2023 Category: Gastroenterology Source Type: research
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
ConclusionPreoperative DOS followed by surgery and postoperative S-1 may be considered a treatment option for LAGC patients regardless of MMR status. (Source: Gastric Cancer)
Source: Gastric Cancer - October 27, 2023 Category: Gastroenterology Source Type: research
A nonrandomized controlled trial: long-term outcomes of LATG/LAPG for cStage I gastric cancer: Japan Clinical Oncology Group Study JCOG1401
ConclusionsThis single-arm study showed that the long-term outcomes of LATG/LAPG for cStage I gastric cancer were acceptable, which is considered one of the standard treatments when performed by experienced surgeons.Trail registration UMIN000017155 (http://www.umin.ac.jp/ctr/). (Source: Gastric Cancer)
Source: Gastric Cancer - October 25, 2023 Category: Gastroenterology Source Type: research
Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor –adipocyte interaction indicating an altered immune response
ConclusionsSARIFA proves to be a strong negative prognostic biomarker in advanced gastric cancer, implicating an interaction of tumor cells with tumor-promoting adipocytes with crucial changes in tumor cell metabolism. SARIFA is not driven by tumor genetics but is very likely driven by an altered immune response as a causative mechanism. (Source: Gastric Cancer)
Source: Gastric Cancer - October 24, 2023 Category: Gastroenterology Source Type: research
